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 INTRODUCTION: 
 
“Nonalcoholic fatty liver disease (NAFLD) is emerging as an important cause of liver 
disease in India. Epidemiological studies suggest prevalence of NAFLD in around 9% 
to 32% of general population in India with higher prevalence in those with 
overweight or obesity and those with diabetes or prediabetes”.  
 
“Non Alcoholic Fatty Liver Disease (NAFLD) is a disease characterized by excessive 
deposition of fat (steatosis) within the hepatocytes . This disease comprises a wide range 
of pathological changes rangingfrom steatosis to Non Alcoholic Steatohepatitis(NASH) 
with inflammation of the liver.The most common cause of death in patients with NAFLD 
is cardiovascular death accounting for 48% of mortality while liver related deaths occur 
only in 7% of the patients”. 
 
“Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) 
are associated with cardiovascular events and Metabolic Syndrome (MetS). NAFLD is 
considered to be a hepatic manifestation of MetS and has become an important public 
health issue because of its high prevalence. It is currently being considered an 
independent Cardiovascular disease (CVD) risk factor.” 
 
“Obesity, type 2 diabetes mellitus and hyperlipidaemia are coexisting conditions 
frequently associated with NAFLD. Because of the strong association with 
various metabolic abnormalities, NAFLD is now considered a part of spectrum of 
metabolic syndrome . Patients with metabolic syndrome are at an increased risk for 
atherosclerosis and cardiovascular disease. In the Third National Health and Nutrition 
Examination Survey, metabolic syndrome was significantly related to myocardial 
infarction in either gender. In the Atherosclerosis Risk in Communities (ARIC) study, the 
subjects with metabolic syndrome were approximately 1.5–2 times more likely to 
develop coronary artery disease  than the controls.This puts patients with NAFLD also at 
an increased risk for atherosclerosis and cardiovascular disease.” 
 
“Mean Platelet Volume (MPV) is an indicator of platelet function and activation.  
Platelets play a vital role in hemostasis and mean platelet volume (MPV) is a measure of 
average size and platelet activity. Larger platelets are more thrombogenic and contribute 
to atherosclerosis.The cause of increased MPV in patients with NAFLD is due to low 
grade inflammatory state induced by hepatic steatosis leading to platelet 
activation.Increase in MPV is also well documented in metabolic syndrome, stroke and 
diabetes mellitus .It is a simple test that can be done during routine Complete Blood 
Count. Hence, MPV can be used as simple and cost-effective hematological parameter 
for predicting cardiovascular events”.  
 
“Thus this study is done to compare MPV values of the patients with NAFLD and of the 
patients without fatty liver disease and to investigate whether this increased MPV is 
associated with increased cardiovascular disease in patients with NAFLD “. 
REVIEW OF LITERATURE 
“According to Practice Guideline by the American Association for the Study of Liver 
Diseases, American College of Gastroenterology, and the American Gastroenterological 
Association Non alcoholic fatty liver disease and related disease‟s definition are as 
follows  
NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) Encompasses the entire 
spectrum of fatty liver disease in individuals without significant alcohol consumption, 
ranging from fatty liver to steatohepatitis and cirrhosis.” 
 
“Ongoing or recent alcohol consumption > 21 drinks on average per week in men and > 
14 drinks on average per week in women is a reasonable definition for significant alcohol 
consumption when evaluating patients with suspected NAFLD in clinical practice”. 
 
“NONALCOHOLIC FATTY LIVER  (NAFL) is defined as the presence of hepatic 
steatosis with no evidence of hepatocellular injury in the form of ballooning of the  
 
 hepatocytes or no evidence of fibrosis. The risk of progression to cirrhosis and liver 
failure is minimal”. 
“ NONALCOHOLIC STEATOHEPATITIS (NASH) indicates the presence of hepatic 
steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis. 
This can progress to cirrhosis, liver failure and rarely liver cancer.”  
“NASH CIRRHOSIS is the presence of cirrhosis with current or previous histological 
evidence of steatosis or steatohepatitis”  
“Cryptogenic Cirrhosis is the presence of cirrhosis with no obvious etiology. Patients 
with cryptogenic cirrhosis are heavily enriched with metabolic risk factors such as 
obesity and metabolic syndrome”.  
“NAFLD Activity Score (NAS): An unweighted composite of steatosis, inflammation, 
and ballooning scores. It is a useful tool to measure changes in liver histology in patients 
with NAFLD in clinical trials”. 
“Therefore to define a patient having NAFLD there should be evidence of hepatic 
steatosis either by imaging or by histology and there should not be any cause of 
secondary hepatic fat accumulation such as significant alcohol consumption , use of 
steatogenic medications or hereditary disorders.” 
 
 “ NAFLD is assuming higher importance now because of:  
1. The possible role in the development of cardiovascular disease 
 2. The association with diabetes and impaired glucose tolerance 
3. The strong relationship with metabolic syndrome.” 
 
“CARBOHYDRATE DEFICIENT TRANSFERRIN (CDT) is a specific biomarker of 
chronic alcohol abuse. It has a half life of more than 15 days. The presence of high levels 
of CDT excludes the diagnosis of NAFLD.” 
 
“EPIDEMIOLOGY OF NAFLD: 
The prevalence of NAFLD is rapidly increasing worldwide in parallel with the increase 
in obesity and type 2 diabetes . It is important to note that this prevalence is partly 
dependent upon the method used to diagnose NAFLD, the method used to assess alcohol 
intake and the cutoff point used to exclude „relevant‟ alcohol intake . The prevalence of 
NAFLD in the general population is estimated to be 20–30% in Western countries  and 
15% in Asian countries” .  
 
  
 
 
“The prevalence of NAFLD varies according to age, gender and weight status. NAFLD 
and the NASH have been reported in subjects of all ages, including children, where the 
prevalence of steatosis is smaller than in adults (13–15%), but increases in presence of 
obesity (30–80%) . As a rule, the prevalence of NAFLD increases with age, with higher 
values in males between 40 and 65 years. The most reliable values for the prevalence of 
NAFLD and NASH in the general population are 20–30% and 2–3%, respectively. 
Owing to the increased prevalence and incidence of obesity and diabetes, in the next few” 
years NAFLD may represent the principal cause of liver disease worldwide and possibly 
the first cause of liver transplantation . 
 
 
 
 
 
 ESTIMATED PREVALANCE OF NAFL, NAFLD, NASH 
 
 
 
 
 
 
 
  
 
INDIAN SCENARIO: 
“The prevalence of NAFLD in india is around 10-32%,according to NHANES data ,the 
prevalence of NAFLD has been increasing over the past 3 decades accounting to nearly 
50 to 75% of chronic liver disease.diabetes,central obesity,insulin resistance and 
dyslipidemia are common predisposing factors.India has the largest number of people 
with diabetes in the world.Asian Indians are more prone to have insulin resistance and 
have increased waist circumference and visceral fat.With increasing obesity and 
diabetes,there is a high possibility of thr prevalence of fatty liver increasing further”. 
 
NATURAL HISTORY OF NAFLD 
“A major focus of the NAFLD-related chronic diseases during the last 10 years has 
involved chronic liver disease, cardiovascular disease (CVD) and T2DM; e.g., a recent 
meta-analysis showed that NAFLD increased overall mortality by 57% mainly from liver 
related and CVD causes, and increased risk of incident T2DM by approximately twofold 
.There is  emerging evidence that NAFLD is linked to other chronic diseases, such as 
sleep apnea, colorectal cancers, osteoporosis, psoriasis and various endocrinopathies 
(e.g., polycystic ovary syndrome), CKD” 
 
 
   
                                          NATURAL HISTORY OF NAFLD 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
RISK FACTORS ASSOCIATED WITH NAFLD 
 
 
Conditions with established association: 
1. Obesity  
2.Type 2 diabetes mellitus 
 3.Dyslipidemia  
 4.Metabolic syndrome. 
 
 Conditions with emerging association: 
1. Polycystic ovary syndrome  
2. Hypothyroidism  
3.Obstructive Sleep apnea  
4.Hypopituitarism 
5.Hypogonadism  
6.Pancreato-duodenal resection 
 
 
  
 
                         PRIMARY AND SECONDARY RISK FACTORS FOR NAFLD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
COMMON PATHOGENIC MECHANISMS FOR NAFLD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 “Hepatic steatosis is a prerequisite to making a histological diagnosis of NAFLD . 
Several mechanisms may lead to steatosis, including (1) increased fat supply such as 
high-fat diet and excess adipose lipolysis; (2) decreased fat export in the form of very low 
density lipoprotein-triglyceride; (3) decreased free fatty 𝛽-oxidation; and (4) increased de 
novo lipogenesis (DNL) . Certain cytokines derived from inflammation sites, particularly 
from extrahepatic adipose tissues, can trigger steatosis.. In addition, the enhancement of 
hepatic DNL is deemed to be a unique feature in steatosis. Insulin resistance is 
responsible for the massive metabolic dysregulations of NAFLD that initiate and 
aggravate hepatic steatosis. At a certain point, the simple steatosis transforms to 
steatohepatitis in about 20–30% of NAFLD patients.This breakthrough-like process is 
mediated by the interplay of multiple hit factors”. 
 
 
ADIPOSE TISSUE INFLAMMATION : 
 
“Hypoxia and death of rapidly expanding adipocytes are responsible for adipose tissue 
inflammation.. Adipocytes under inflammation secrete cytokines and chemokines, 
particularly tumor necrosis factor-𝛼 (TNF-𝛼), interleukin-6 (IL-6), and CC chemokine 
ligand-2 (CCL2) . TNF-𝛼 is involved in the regulation of insulin resistance. IL-6 is 
derived from many cells including adipocytes and IL-6 have been shown to regulate 
hepatic insulin resistance via upregulation of SOCS3, a suppressor of cytokine signaling. 
CCL2 recruits macrophages to the adipose tissue, resulting in even more local cytokine 
production and perpetuating the inflammatory cycle; TNF-𝛼 and IL-6 induce a state of 
insulin resistance in adipocytes, which stimulates triglyceride lipolysis and fatty acid 
release into the circulation. At the same time, extrahepatic adipocytes are compromised in 
their natural ability to secrete adiponectin, an anti-inflammatory adipokine that facilitates 
the normal partitioning of lipid to adipocytes for storage . Circulating adiponectin 
regulates hepatic fatty 𝛽-oxidation through AMP-activated protein kinase (AMPK) and 
acetyl-CoAcarboxylase (ACC) signaling. Together, these abnormalities accentuate fat 
loss from adipocytes and promote ectopic fat accumulation.” 
 
 
 
 
 DE NOVO LIPOGENESIS (DNL): 
 
 “Diets enriched in both saturated fat and simple sugar carry a high risk of hepatic 
steatosis, through enhanced DNL . Since carbohydrates are substrates for DNL, the 
amount of carbohydrate in the diet will positively influence the amount of DNL in the 
liver. Simple sugars are converted to fatty acids more readily than complex carbohydrates 
and fructose is a more potent inducer of DNL than glucose .  Dietary fat, particularly 
saturated fat, stimulates DNL by upregulating SREBP-1 (sterol responsive element 
binding protein), a key regulator of the lipogenic genes in the liver.” 
 
 
 
 
  
INSULIN RESISTANCE: 
 
“Insulin resistance  is caused by  variety of factors, including soluble mediators derived 
from immune cells and/or adipose tissue, such as TNF-𝛼 and IL-6 . Serine   
phosphorylation of insulin receptor substrates by inflammatory signal transducers such 
as c-jun N-terminal protein kinase 1 (JNK1) or inhibitor of nuclear factor-𝜅B kinase-𝛽 
(IKK-𝛽) is considered one of the key aspects that disrupts insulin signaling.  Insulin 
resistance is characterized not only by increased circulating insulin levels but also by 
increased hepatic gluconeogenesis, impaired glucose uptake by muscle, and increased 
release of free fatty acids and inflammatory cytokines from peripheral adipose tissues , 
which are the key factors promoting accumulation of liver fat and progression of hepatic 
steatosis” . 
 
 
LIPOTOXICITY: 
 
“Long-chain saturated fatty acids (SFAs) such as palmitate (C16:0) and stearate (C18:0) 
are toxic to liver. Under physiological conditions, SFAs are transported to mitochondria 
for 𝛽-oxidation or esterified for either excretion in the form of VLDL (very low density 
lipoproteins) or storage as lipid droplets. Free cholesterol accumulation leads to liver 
injury through the activation of intracellular signaling pathways in Kupf fer cells (KCs), 
hepatic stellate cells (HSCs), and hepatocytes. The activation of KCs and HSCs promotes 
inflammation and fibrogenesis . Excessive SFA,can activate a variety of intracellular  
 responses such as JNK1 and a mitochondrial death pathway, resulting in lipotoxic stress 
in the endoplasmic reticulum and mitochondria, respectively . In addition, the toll like 
receptor 4 (TLR4) is a pattern recognition receptor that activates a proinflammatory 
signaling pathway in response to  excessive SFAs. This pathway is initiated by recruiting 
adaptor molecules such as toll/IL-1 receptor domain containing adaptor protein (TIRAP) 
and myeloid differentiation factor88(MyD88) that ultimately lead to activation of nuclear 
factor 𝜅B with production of TNF-𝛼 .” 
 
MITOCHONDRIAL DYSFUNCTION: 
“Multiple studies have shown that liver ATP levels are decreased in NAFLD . This 
implicates mitochondrial dysfunction in the state of liver fat overload that is characteristic 
of NAFLD. Reduced enzymatic activities of mitochondrial electron transport 
chain (ETC) complexes  attributes to increased generation of reactive oxygen species 
(ROS) as a result of ETC leakage during mitochondrial 𝛽-oxidation in energy 
production . ROS can damage the ETC and even cause mutations in  the mitochondria 
DNA.” 
 
 
OXIDATIVE STRESS: 
 “Increased supply of fatty acids to hepatocytes, leads to oxidative stress due to raised 
levels of reactive oxygen/nitrogen species (ROS/RNS) and lipid peroxidation that are  
 generated during free fatty acid metabolism in microsomes, peroxisomes, and 
mitochondria . Peroxidation of plasma and intracellular membranes may cause direct cell 
necrosis/apoptosis and mega mitochondria, while ROS-induced expression of Fas-ligand 
on hepatocytes may induce cell death”. 
 
 
ENDOPLASMIC RETICULUM (ER) STRESS: 
“Under  stressful conditions such as NASH, it has been observed that ER efficiency in the 
protein folding, repairing, and/or trafficking machinery is decreased while the demand of 
protein synthesis and folding/repair is increased . Such an imbalance is termed ER stress, 
which can lead to the accumulation of unfolded and/or misfolded proteins within the ER 
lumen.This type of cellular stress usually triggers an adaptive response, aimed at 
resolving ER stress, called unfolded protein response (UPR) .” 
 
“The UPR is mediated by at least three different stress-sensing pathways: protein kinase 
RNAlike ER kinase (PERK), inositol-requiring protein 1𝛼 (IRE1𝛼), and activating 
transcription factor 6 (ATF6) . Coupled with inflammation, oxidative stress, insulin 
resistance, and apoptosis signaling, hepatic ER stress seems to play an important role in 
regulating the composition and size of lipid droplets as well as lipid synthesis, including 
cholesterol metabolism , through SREBP.” 
 
MICROBIOTA ASSOCIATED MECHANISMS OF NAFLD 
 
“Gut microbiota may contribute to the pathogenesis of NAFLD through several 
mechanisms, 
 (1) increased production and absorption of gut short-chain fatty acids; 
 (2) altered dietary choline metabolism by the microbiota;  
(3) altered bile acid pools by the microbiota;  
(4) increased delivery of microbiota derived ethanol to liver;”  
“(5) gut permeability alterations and release of endotoxin; and 
 (6) interaction between specific diet and microbiota 
(7) chronic kidney disease may mutually aggravate NAFLD and associated metabolic 
disturbances through multiple paths including altered intestinal barrier function and 
microbiota composition.” 
 
GENETIC FACTORS: 
In NAFLD,  two genes (PNPLA3 and TM6SF2) have been identified as potential genetic 
modifiers. 
 PNPLA3 (PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING3). 
 “The PNPLA3 gene (adiponutrin) encodes a transmembrane polypeptide chain 
exhibiting triglyceride hydrolase activity , which is highly expressed on the endoplasmic 
reticulum and lipid membranes of hepatocytes and adipose tissue .  The encoded protein 
has retinyl esterase activity and allows retinol secretion from hepatic stellate cells while 
the mutation causes intracellular retention of this compound . The association between 
the PNPLA3 variant and steatosis or severity of histological liver disease has been widely 
observed The link between PNPLA3 I148M variant and NAFLD is independent of 
metabolic syndrome (MS) and its features; that is, most of patients carrying this variant 
are not associated with obesity, diabetes, and atherogenic dyslipidemia. Furthermore, the 
PNPLA3 genotype seems to also influence steatosis development in patients with  
hepatitis B and hepatitis C and alcohol abuse, and it has been independently associated 
with the progression of hepatitis, including fibrosis, cirrhosis, and HCC .The association 
between the PNPLA3 variant I148M and the risk of HCC development has been robustly 
validated in patients with NAFLD.” 
 
 TM6SF2 (TRANSMEMBRANE 6 SUPERFAMILY MEMBER 2): 
“Silencing of the gene showed a 3-fold increase in hepatic triglycerides levels and a 
decrease in plasma levels of triglycerides, LDL- and high density lipoprotein- (HDL-) 
cholesterols, and very low density lipoprotein (VLDL).  TM6SF2 gene regulates 
hepatic triglyceride secretion and that the functional impairment of TM6SF2 promoted 
NAFLD.”  
 
CLINICAL FEATURES 
“Fatty liver is usually a asymptomatic condition. It is the incidental finding in most of the 
patients. In symptomatic patients , they present with right upper quadrant pain , malaise , 
fatigue and bloating. There may be associated hepatomegaly and one or more 
components of metabolic syndrome may be present. Presence of liver cell failure like  
  
 
 
 
ascites , palmar erythema , spider angioma indicates associated cirrhosis. Splenomegaly 
may be present in small percentage of individuals.” 
 
 
 
DIAGNOSIS OF NAFLD: 
The diagnosis of NAFLD requires that  
(a) there is hepatic steatosis by imaging or histology, 
 (b) there is no significant alcohol consumption, 
 (c) there are no competing etiologies for hepatic steatosis, and (d) there are no co-
existing causes for chronic liver disease. 
 
 
 
 
 
 
  
                                        DIAGNOSTIC APPROACH 
LABORATORY FEATURES OF NAFLD 
 “Suspicion for NAFLD is triggered by abnormalities of liver chemistry tests that are 
usually performed for non liver-related reasons. About 50% of patients with simple 
steatosis have higher liver biochemical test levels, which occur in 80% of patients with 
advanced NAFLD. Also, serum aspartate aminotransferase or ALT level, or both is 
usually increased up to 1.5- to 4-fold and levels rarely exceed 10 times the upper limit of 
normal. However, the gamma glutamyl transpeptidase and alkaline phosphatase levels 
may be elevated, but the serum prothrombin time, bilirubin level and serum albumin level 
are normal, except in patients with NAFLD-associated cirrhosis. Serum ferritin level may 
be higher in 20% to 50% of NAFLD patients and can be considered a marker for 
advanced disease. Hyperglycemia and dyslipidemia may be detected in 30% to 50% of 
NAFLD subjects. Laboratory and clinical findings do not correlate with NAFLD 
histologic severity.” 
 
IMAGING FEATURES OF NAFLD  
“The radiologic features of fatty liver disease stem from the increased fat content of the 
liver parenchyma. The spatial pattern may be diffuse and homogeneous or heterogeneous, 
with focal fat deposition in an otherwise normal liver or areas of focal fat sparing in a 
diffusely fatty liver. The homogeneous form is the most common; the heterogeneous and 
focal forms may simulate perfusion abnormalities, diffusely infiltrative disease, nodular 
lesions, or masses. The most important modalities used in the assessment of hepatic 
steatosis are ultrasonography, computed tomography (CT), and magnetic resonance (MR) 
imaging and MR spectroscopy.”  
 
“Transabdominal ultrasonography is the most common imaging technique to diagnose 
hepatic steatosis due to its widespread availability, noninvasiveness and low cost. At 
ultrasonography, diffuse fatty liver is characterized by hyperechogenicity of the liver 
parenchyma relative to the adjacent right kidney or spleen (the so-called bright liver). 
Focal fat deposition appears as a hyperechoic area in an otherwise normal liver, whereas 
focal fat sparing is represented by a hypoechoic area within diffusely hyperechoic liver 
parenchyma. Other ultrasound features of fatty liver include decreased visualization of 
vascular margins, attenuation of the ultrasound beam, loss of definition of the diaphragm, 
and hepatomegaly .” 
 
USG GRADING OF HEPATIC STEATOSIS: 
“GRADE 1 (mild) : normal visualization of diaphragm / intrahepatic vessels. 
GRADE 2(moderate): impaired visualization of diaphragm/intrahepatic vessels. 
GRADE 3 (severe) : poor  visualization of diaphragm/intrahepatic vessels.” 
 
“Transient elastography, a recently developed technique based on ultrasound monitoring 
of the passage of a low frequency pressure wave through tissues, has been found to be a 
promising non-invasive technique for the detection of advanced fibrosis caused by  
 
  
chronic viral hepatitis and NASH, although abdominal obesity may compromise its utility 
in the NASH patient population.” 
 
HISTOLOGICAL FEATURES OF NAFLD 
 
 “The main histologic features of NAFLD are similar to those of alcohol-induced liver 
disease and include steatohepatitis (fatty liver plus parenchymal inflammation with or 
without accompanying focal necrosis), steatosis (fatty liver) and varying degrees of 
fibrosis, including cirrhosis. Steatosis is predominantly macrovesicular and usually is 
distributed diffusely throughout the liver lobule, although prominent microvesicular 
steatosis and zone 3 (perivenular) steatosis have been reported . Mild neutrophilic, 
lymphocytic, or mixed inflammatory infiltrates also may be observed, and glycogenated 
nuclei are common. NASH, which is an advanced form of NAFLD, is indistinguishable 
histologically from alcoholic hepatitis .” 
 
 
 
 
 
 
                                               SIMPLE STEATOSIS 
 
 
 
 
                          NON ALCOHOLIC STEATOHEPATITIS 
 
 
  
 
 
 
 
 
 
HISTOLOGICAL GRADING FOR NASH 
 
 
 
 
 
“The standardized schema of NAFLD staging and grading was published by Brunt and 
associates in 1999, who assigned the overall grade of mild, marked, or severe (grades 1, 
2, and 3, respectively), based on the degree of ballooning degeneration, steatosis and 
lobular and portal inflammation.” 
 
NON INVASIVE TESTS 
“1.  Fibro test – estimates serum haptoglobin , total bilirubin , α2 macroglobulin , 
apolipoprotein A1 and GGTP. 
2. necro inflammatory activity index – estimates above mentioned markers and ALT. 
3. NAFLD FIBROSIS SCORE – Age ,BMI , AST/ALT ratio , platelet count and serum 
albumin. 
4. Fibroscan 
5.Serum Dehydroepiandrosterone 
6.Serum hyaluronic acid.” 
 
 
 
 
 
 
 
 
 DIFFERENTIAL DIAGNOSIS: 
 
 
 
NAFLD AND METABOLIC SYNDROME: 
  
“Metabolic syndrome, (Syndrome X ) or insulin resistance syndrome is defined as a 
group of metabolic abnormalities with insulin resistance and abdominal obesity.There is 
relationship between metabolic syndrome and NAFLD.This is reflected by the fact that 
more than 90% of those with NAFLD have one or more features of metabolic syndrome 
and 33%have three or more features.” 
 
“Insulin resistance is the main component of metabolic syndrome, which favours 
compensatory hyperinsulinemia by increased production in the pancreatic beta cells and 
decreased degradation in the liver.Since the same pathophysiological features apply in the 
development of NAFLD,it is now considered as the hepatic component of metabolic 
syndrome. The presence of metabolic syndrome leads to progressive and severe liver 
disease increasing the likehood of developing NASH and cirrhosis.” 
 
 
 
 
 
 
 
 
NAFLD AND OBESITY: 
“Obesity is defined as abnormal and excessive accumulation of fat that poses a risk to 
health . BMI is a simple index used to classify overweight and obesity. It is defined as a 
person‟s weight in kilograms divided by the square of his height in metre (kg/ sq,m) . it 
can also be measured by triceps skin fold thickness , midarm circumference , waist 
circumference and waist hip ratio. Visceral fat can be assessed by CT and MR 
spectroscopy.”  
 
“Fat distribution in the body plays a pivotal role in the complications and morbidity . 
visceral fat and abdominal fat are given particular importance in this regard . visceral fat 
is biologically more active , high lipolytic activity and secretes adipocytokines . hence 
there is more production of fatty acids and glycerol which reach the liver through the 
portal vein and lead to steatosis . subcutaneous fat has less adipocyte activity than 
visceral fat. Obesity associated inflammation recruits macrophages into cells inducing 
endoplasmic stress and making the cell resistant to insulin . macrophages are more in 
number in visceral fat and promote insulin resistance.” 
 
“Complex humoral and neural mechanisms are involved in the pathogenesis of obesity. 
Leptin is synthesized in fat cells in response to abundant fat stores which stimulates 
physical activity , energy production and heat production . adiponectin , another  
adipocytokine directs fatty acids to muscle for oxidation . Any alteration in these process 
leads to obesity. Gherlin is another gut hormone which increases food intake , whose post 
prandial suppression when attenuated leads to obesity.” 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
NAFLD AND ATHEROSCLEROSIS: 
“Atherosclerosis is defined as loss of elasticity of the arterial wall and associated with 
thickening . it can affect any vessel in the body including those supplying the heart 
leading to coronary artery disease , brain resulting in stroke and peripheral arteries. It is 
considered to be the major cause of death and premature morbidity in developed 
countries. Atherosclerosis is considered to be a slow process which evolves over years. 
The initiating event is the endothelial injury . Endothelial injury can be caused by various 
factors that in turn leads to endothelial dysfunction.”  
 
“Endothelial dysfunction is considered to be one of the initial components of the 
inflammatory process that results in atherosclerosis. It is characterized by impaired 
endothelial relaxation , increased vascular permeability and increased expression of the 
circulating adhesion molecules. This derangement leads to accumulation of lipoproteins 
in the initima of major arteries which forms the precursor for atherosclerotic plaque , 
fatty streak.” 
 
“These lipoproteins trigger local inflammatory response giving rise to recruitment of 
mononuclear cells into the intima. The mononuclear cells elaborate a number of 
cytokines that stimulate smooth muscle proliferation and production of extracellular 
matrix leading to the complex atherosclerotic lesion . the products of coaguulaion and 
thrombosis complicate further process.” 
“Dyslipidemia is one of the established risk factors for atherosclerosis . atherogenic 
dyslipidemia is considered when there is a combination of raised triglycerides , low levels 
of HDL c with apoliprotein B , small dose LDL and small HDL particles. Apart from the 
established risk factors , lipoprotein (a) , prothrombotic factors , homocysteine , 
proinflammatory factors and impaired fasting glucose are proposed to be emerging risk 
factors for atherosclerosis.” 
 
NAFLD AND CARDIOVASCULAR DISEASE : 
“The CVD is characterized by critically narrowing (stenosis) or occlusion 
(atherothrombosis) of blood vessels. Key processes in CVD are endothelial dysfunction, 
atherosclerosis, and impaired regulation of coagulation and fibrinolysis. The complement 
system may be involved in all these processes based on its immune, inflammatory and 
metabolic functions. Systemic complement levels may be involved in coagulation and 
fibrinolysis, which together with endothelial dysfunction and atherosclerosis result in 
cardiovascular disease.The complement-C3 has shown independent associations with 
insulin resistance, liver dysfunction and in the risk of Metabolic Syndrome  and T2DM. 
Circulating levels of several inflammatory markers (C reactive protein, interleukin-6, 
monocyte chemotactic protein 1, and TNF-a), procoagulant factors (plasminogen 
activator inhibitor 1, fibrinogen, and factor VII), and oxidative stress markers are highest 
in patients with NASH independent of obesity and other potentially confounding factors. 
NAFLD seems to be not simply a marker of cardiac and arrhythmogenic complications 
but also may play a part in their pathogenesis possibly via atherogenic dyslipidemia and 
the hepatic secretion of several pathogenic mediators”. 
 
“Central obesity can provoke inflammation and insulin resistance in adipose tissue and 
the release of proinflammatory adipokines and Free Fatty Acids (FFAs). Liver fat is 
associated with an increased number of higher small dense LDL (sdLDL) particles, 
which have higher atherogenic properties than larger less dense LDL-C particles. These 
lipoproteins are associated with increased activity of hepatic lipase favoring the 
production of sdLDL particles. Patients with NASH can have the transcriptional 
regulation of proatherogenic genes altered and it is associated with the activation of 
molecular events that may also be responsible for the local production of mediators or 
modifiers of circulatory homeostasis.” 
 
“The atherogenecity of the increase in sdLDL is likely to be further compounded by  
decrease in LDL receptor expression in NASH.From a cardiovascular point of view the 
direct relation between LDL-C and HMGCR expression suggests that the liver disease 
contributes to LDL-mediated cardiovascular risk.” 
 
NAFLD, CARDIAC ARRHYTHMIAS AND AORTIC VALVE SCLEROSIS 
 
“Recently, mildly elevated liver transaminases have been shown to be independently 
associated with increased incidence of atrial fibrillation (AF) in the Framingham Heart 
Study cohort . Finally, the presence of aortic valve sclerosis, i.e., a progressive disease 
that shares multiple pathogenic risk factors with CVD and is associated with an increased 
risk of CVD mortality has also been linked with NAFLD, independently of established 
CVD risk factors, in both diabetic and nondiabetic individuals.” 
 
“Therefore  the liver represents a contributor to systemic inflammatory changes, insulin 
resistance and hyperlipidemia determining a progression of vascular diseases and 
atherosclerosis. NAFLD/NASH are associated with an increased risk of incident 
cardiovascular disease, independently of the traditional risk factors.” 
 
 
 “NAFLD patients  have significantly higher carotid artery intima-media thickness (IMT), 
a marker of subclinical atherosclerosis, comparing with those without fatty liver impaired 
endothelial function, and lower concentrations of adiponectin. IMT is strongly associated 
with degree of hepatic steatosis, necro inflammation, and fibrosis among NAFLD 
patients” 
 
“ NAFLD patients have  strong association with early carotid atherosclerosis, 
independent of classical risk factors,insulin resistance, and the presence of metabolic 
syndrome. Plasma concentrations of high-sensitivity C-reactive protein (hs-CRP), 
fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) with biopsy-proven NASH. 
Also, the highest concentrations of adiponectin were found in biopsy proven 
NAFLD.Abnormal left ventricular energy metabolism, fat accumulated in the epicardial 
area despite normal left ventricular morphological features, and systolic and diastolic 
function.” 
 
NAFLD AND DIABETES MELLITUS: 
“NAFLD is strongly associated with T2DM and cardiovascular disease (CVD). It is 
characterized by insulin resistance and mitochondrial dysfunction .  There is a gradual 
increase in the severity of insulin resistance in the range of NAFLD which may 
contribute to the evolution of liver damage. Also, is associated with an increased risk of 
kidney disease in subjects with multiple CVD risk factors and tends to be considered as 
an independent CVD marker. Diabetes, dyslipidemia, hypertension and CVD coexist 
more frequently in individuals with NAFLD” 
 
 
 
 
 
. 
 putative mechanisms underlying the contribution of NAFLD to the increased risk of 
cardiovascular disease (CVD), chronic kidney disease (CKD) and other structural and 
arrhythmic cardiac complications 
 
 
 
 
 
 
 
DIET AND NAFLD: 
 
“Change in dietary pattern plays a crucial role in the exponentially increasing incidence 
of obesity. The use of refined carbohydrates produces more energy per serving at the 
expense of causing hyperinsulinemia. Increase in dietary fat produces more calories per 
gram , presence of trans fat improves the taste but are not metabolized in the body. 
The presence of dietary fibres decreases post prandial insulin surge and lipogenesis . but 
dietary fibre consumption had reduced over the recent years contributing to obesity . The 
use of monosodium glutamate enhances taste and flavor in foods have been found to 
increase appetite. Fructose in fruit and soft drinks inhibits the suppression of gherlin and 
delays satiety. It is also converted to fructose 1 phosphate  without regulation leading to 
lipogenesis , fatty liver and insulin resistance.” 
 
 
 
 
 
 
 
 
 
 
MANAGEMENT STRATGIES: 
 
 
 
 
 
 
 
TREATMENT OPTIONS FOR NAFLD: 
 
 
 
 
 
 
  
 
TREATMENT OF TYPE 2 DIABETES AND METABOLIC SYNDROME IN 
NAFLD PATIENTS: 
 
 
 
  
MANAGEMENT OF HYPERTENSION AND DYSLIPIDEMIA IN NAFLD 
PATIENTS: 
 
 
 
 
 
 
 
 
 
 AIM AND OBJECTIVES OF OUR STUDY: 
 
1.To assess the association of MPV in NAFLD patients. 
2.To investigate whether this increased MPV is associated with increased 
cardiovascular disease in patients with NAFLD . 
 
MATERIALS AND METHODS; 
STUDY POPULATION: 
The present study is going to be conducted on patients admitted in MGE/Medicine 
wards or attending outpatient departments  of  Government Rajaji Hospital, 
Madurai during the period of  March2016 to August2016. 
INCLUSION CRITERIA: 
“Age>18 yrs 
Hepatosteatosis proven by USG abdomen 
No medication history 
No alcohol consumption 
No viral hepatitis.” 
EXCLUSION CRITERIA: 
“Alcohol consumption more than  40 g/wk. 
Viral hepatitis. 
Hepatotoxic drugs. 
Women on OCP. 
Autoimmune hepatitis. 
Metabolic Liver disease. 
Pregnancy. 
Hepatobiliary surgery” 
 
ANTICIPATED OUTCOME: 
Patients with NAFLD have increased MPV and this is associated with 
increased cardiovascular risk. 
 
 
 
METHODS: 
“A previously designed proforma was used to collect the demographic and 
clinical details of the patients. All the patients will undergo detailed clinical 
evaluation, appropriate investigations.” 
“History was taken on details ofalcohol consumption,blood transfusion ,IV drug 
abuse,diabetes mellitus, use of medications. Fasting blood sugar, liver function 
tests including serumbilirubin, serum transaminases,viralmarkers,fasting lipid 
profile was  estimated.Degree of hepatosteatosis was evaluated by ultrasound scan 
and from  laboratory data of patients with NAFLD obtained at the time of 
diagnosis.”  
 
LABORATORY INVESTIGATIONS: 
1.Blood sugar 
2. platelet count. 
3.Liver enzymes and viral markers. 
4. Fasting lipid profile. 
5.Mean platelet volume. 
“For the above mentioned hematological parameter , 2 ml of blood was 
withdrawn by venepuncture from the patients within 24 hours of admission to 
the hospital. The venepuncture site was properly cleaned and blood withdrawn 
and collected in EDTA containing disposable tubes . the sample was 
transported immediately to qualified controlled centre where the sample was 
analysed for platelet volume. The instrument used for analysis was COBAS 
MICROS OT 18 automated hematological analyser made by ROCHE.”  
“The instrument was started up . after starting , a pipette appeared from the 
instrument . blood sample was fed to the instrument by the principle worker . 
the pipette draw the necessary amount of blood and withdrew on its own after 
taking necessary amount of blood . from that moment a waiting period of 180 
seconds appeared on the screen. At the end of 180 seconds , a print out with the 
platelet count and mean platelet volume was ejected from the printer connected 
to the instrument. The instrument was repeatedly standardized for quality 
control”. 
STASTICAL ANALYSIS: 
“The data collected during the study was formulated into a master chart in 
Microsoft office excel and statistical analysis was done with help of computer 
using stastistical software packages SPSS V.17 software.” 
 DESIGN OF STUDY: 
Cross sectional study 
PERIOD OF STUDY: 
March2016 To August  2016 ( 6 months) 
COLLABORATING DEPARTMENTS: 
Department of Medical gastroenterology. 
Department of Biochemistry 
Department of Microbiology. 
Department of Radiology. 
Department of  Pathology.   
ETHICAL CLEARANCE: 
 Necessary ethical clearance was obtained from the ethical committee, GRH , 
Madurai. 
CONSENT:  
Individual written and informed consent. 
ANALYSIS:STATISTICAL ANALYSIS. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  SELF 
PARTICIPANTS: 
The present study was conducted on patients admitted in MGE/Medicine wards or 
attending outpatient departments of  Government Rajaji Hospital, Madurai during 
the period of  March 2016 to August 2016. 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS : 
TABLE 1 : AGE DISTRIBUTION IN NAFLD 
AGE NO OF CASES 
<40 13 
41-50 43 
51 - 60   32 
> 60  12 
Total 100 
Mean 49.21 
 
Among 100 patients, 56% of patients age lies between 40 to 50 years. 
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TABLE 2 SEX DISRTIBUTION: 
 
SEX NO OF CASES 
Male 72 
Female 28 
Total 100 
 
Among 100 patients 72% were males and 28% were females. This indicates that NAFLD 
is common among men. 
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TABLE 3 : BMI DISTRIBUTION  
 
BMI NO OF CASES 
<25 36 
26-30 61 
>30 3 
Total 100 
 
Among NAFLD patients 61% had BMI  in the range of around 26 to 30.This indicates 
obesity plays major role in the pathogenesis of NAFLD. 
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 TABLE 4:WAIST CIRCUMFERENCE DISTRIBUTION 
 
WAIST CIRCUMFERENCE NO OF CASES 
<75 18 
76-90 50 
>90 32 
Total 100 
 
Among NAFLD 50% had waist circumference in the range of around 76 to 90 cm.this 
indicates central obesity plays major role in pathology of NAFLD. 
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 TABLE 5:FASTING BLOOD SUGAR DISTRIBUTION 
 
 
FBS NO OF CASES 
<100 35 
101-200 52 
>200 13 
Total 100 
 
Among NAFLD  patients 65% had fasting blood sugar >100mg/dl.This indicates diabetes 
mellitus plays role in the pathology of NAFLD. 
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TABLE 6:BLOOD PRESSURE DISTRIBUTION: 
 
SBP 
No Of Cases 
<130 23 
131-150 58 
>150 19 
Total 100 
 
Among NAFLD patients 77% had blood pressure >130 mm hg..This indicates 
hypertension is common association with NAFLD. 
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TABLE  7:DIASTOLIC BLOOD PRESSURE DISTRIBUTION: 
 
 
DBP No Of Cases 
<85 59 
86-100 35 
>100 6 
Total 100 
 
 
Among NAFLD  patients 41% patients have diastolic blood pressure above 85mm/Hg. 
This indicates diastolic hypertension is also common in NAFLD. 
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TABLE 8:ALANINE TRANSAMINASE DISTRIBUTION: 
 
ALT No Of Cases 
<25 56 
26-50 25 
>50 19 
Total 100 
 
Among NAFLD  patients 44% had increased  enzyme activity. This indicates the NAFLD 
patients have chronic inflammation of the liver. 
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TABLE ALT AND MPV CORELATION: 
 
ALT  Mean MPV SD 
<25  (56) 9.816 
1.271 
26-50 (25) 9.444 
1.468 
>50 (19) 10.232 
0.87 
 
In NAFLD patients whose ALT was high , MPV was also tend to be high. This shows the 
positive correlation between ALT and MPV. The mean MPV was 10.2 in elevated ALT 
patients. 
 
 
 TABLE : HDL AND TGL DISTRIBUTION 
 
HDL 
No Of Cases 
<40 66 
41-50 20 
>50 14 
Total 100 
 
 
  
TABLE TGL DISTRIBUTION IN NAFLD PATIENTS 
 
 
TGL 
No Of Cases 
<150 32 
>150 68 
Total 100 
 
Among NAFLD patients  68 % of the patients had TGL >150 mg/dl and 66 % of patients 
have HDL cholesterol < 40 mg.dl. 
 
 
 
TABLE 9:PLATELET  DISTRIBUTION: 
 
PLATELET COUNT No Of Cases 
<2.0 43 
2.1-3.0 38 
>3.0 19 
Total 100 
 
Among NAFLD patients 57% patients had elevated platelet count.This indicates platelet 
abnormality is common among NAFLD  patients. 
 
  
 
 
 
 
 
TABLE 10: MEAN PLATELET VOLUME DISTRIBUTION : 
 
 
 
MPV No Of Cases 
<9.0 30 
9.1-11.0 47 
>11.0 23 
Total 100 
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 Mean platelet volume is increased in 70% patients in NAFLD. This indicates platelet 
volume and atherosclerosis is common among NAFLD patients. 
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 TABLE 11:ELECTRO CARDIOGRAPHIC CHANGES DISTRIBUTION: 
 
 
ECG CHANGES No Of Cases 
P 53 
A 47 
Total 100 
 
53% NAFLD patients had electrocardiographic changes. This indicates NAFLD  is 
associated with cardiovascular disease. Also these ECG changes were associated with 
NAFLD patients with high MPV. 
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TABLE 12:BODY MASS INDEX VERSUS PLATELET COUNT DISTRIBUTION: 
 
BMI VS PLATELET COUNT Mean SD 
P 
<25  (36) 2.186 
0.779 
0.356 26-30 (61) 2.292 
0.771 
>30 (3)  1.667 
0.764 
 
Among obese patients platelet counts were decreased .This indicates that obese 
individuals have platelet dysfunction and they are more prone to early atherosclerosis and 
cardiac morbitity. 
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TABLE 13 :  BMI AND MPV DISTRIBUTION 
 
BMI VS MPV Mean SD 
P 
<25  (36) 8.747 
0.935 
<0.001 26-30 (61) 10.336 
1.023 
>30 (3)  11.6 
0.458 
 
 
Among obese patients MPV was increased. The mean MPV for BMI >30 was 11.6 which 
was significant .This indicates that obese individuals have platelet dysfunction and they 
are more prone to early atherosclerosis and cardiac morbitity. 
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 DISCUSSION: 
 
 
“This study was done in Government Rajaji Hospital which included 100 NAFLD 
patients  who were selected randomly. All laboratory determinations were obtained after 
12 fasting h. Enzymatic methods were used to measure fasting blood glucose, total and 
HDL-cholesterol, and triglyceride . ALT and AST levels were measured using the -
ketoglutarate reaction; GGT levels with the L--glutamyl-3-carboxy-4-nitroaniliderate 
method.” 
 
AGE AND SEX DISTRIBUTION : 
“Among 100 patients , NAFLD are more common in age group of  40 to 50 years ( 56%). 
NAFLD is more common among males (72%) when compared to female (28%). Obesity 
and visceral adiposity were common in males and so NAFLD was common among 
males. Our findings are in agreement with the study Kopley et al, 2011 . However In a 
study  Mean platelet volume as a novel surrogate marker for early Non-Alcoholic 
Fatty Liver Disease conducted by  Walid Shehab-Eldin, Alaa Efat, Somaia 
Shehabeldeen, Abdallah Essa, Mohamed Shereef et al , there was  no significant 
difference as regarding with age, sex.” 
 
 
 
BMI DISTRIBUTION AND METABOLIC SYNDROME AND THEIR 
CORELATION WITH NAFLD 
 
“In our study NAFLD is common among obese individuals with BMI 26 to 30 (61%). 
Among NAFLD patients  68 % of the patients had TGL >150 mg/dl and 66 % of patients 
have HDL cholesterol < 40 mg.dl. Among NAFLD 50% had waist circumference in the 
range of around 76 to 90 cm. This indicates central obesity plays major role in pathology 
of NAFLD. Among obese patients, platelet count was decreased and MPV was increased. 
The mean MPV was 11.6 for BMI>30. This indicates that obese individuals have platelet 
dysfunction and they are more prone to early atherosclerosis and cardiac morbidity.” 
 
“ A previous study in Tehran had shown a strong correlation between NAFLD and BMI. 
The study “Assessment of NAFLD cases and its correlation to BMI and metabolic 
syndrome in healthy blood donors in Kerman” conducted by Sadroddin Lahsaee, 
Alireza Ghazizade et al  found a correlation between NAFLD and metabolic syndrome 
and this is regarding that NAFLD is the hepatic component of metabolic syndrome.” 
 
“In other study  “Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly 
Obese Patients”  conducted by Alexandre Losekann , Antonio C. Weston , Angelo A. de 
Mattos  et all concluded that BMI does not always properly reflect the degree of visceral 
adiposity. The present results did not show a positive correlation of BMI with the degree 
of steatosis, NASH and fibrosis.” 
DIABETES MELLITUS AND NAFLD: 
“Blood glucose was measured by enzymatic photometric test which aimed at determining 
blood glucose after enzymatic oxidation by glucose oxidase. The colorimetric indicator is 
quinoneimine, which is generated from 4-aminoantipyrine and phenol, under the catalytic 
action of peroxidase (Trender's reaction).”  
“In the study , “ Lipid and Glucose Profile in Non-alcoholic Fatty Liver Disease: A 
Hospital Based Study”, sanaa M kamal, Fahad Abdullah Alghulaydhawi, Abdullah 
Omair Alsuayri, Mutlaq Mohammed Almutlaq, Rashed Ibrahim Alqunaian, Abdullah 
Sawma found that NAFLD was closely associated with obesity and diabetes mellitus. 
Diabetes and NAFLD often coexist, and there is evidence to suggest that diabetes can 
have a significant adverse effect on patients with NAFLD, leading to increased 
complications and premature mortality. The liver plays a unique role in controlling 
carbohydrate metabolism by maintaining glucose concentration in a normal range, 
expressing a number of enzymes that are alternatively turned on or off depending on 
whether blood glucose levels are either rising or falling.” 
“In our study also diabetes mellitus was common in NAFLD individuals. Among 
NAFLD  patients 65% had fasting blood sugar >100mg/dl. This indicates diabetes 
mellitus plays role in the pathology of NAFLD.”  
“In a study “Correlation of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus”  
conducted in Kanchipuram , Tamil  nadu , it was statistically proven that there was strong 
co-relation as grading of fatty liver increases there is a marked increase in postprandial 
sugar values. Thus which reveals that prevalence of diabetes mellitus is more when the 
severity of fat accumulation increases in the liver.” 
 
HYPERTENSION AND NAFLD: 
“In our study, among  NAFLD patients 77% had systolic blood pressure >130 mm Hg. 
This indicates hypertension is common association with NAFLD.” 
ALT AND NAFLD: 
“In our study , among NAFLD  patients 44% had increased  enzyme activity. This 
indicates the NAFLD patients have chronic inflammation of the liver.  Also in our study 
in  NAFLD patients whose ALT was high , MPV was also tend to be high. This shows 
the positive correlation between ALT and MPV. The mean MPV was 10.2 in elevated 
ALT patients.” 
“In a study  “Assessment of NAFLD cases and its correlation to BMI and metabolic 
syndrome in healthy blood donors in Kerman” , the prevalence of NAFLD among 35 
subjects with persistently elevated serum ALT level was 63%. It seems that NAFLD is 
the most common cause of a persistently elevated ALT in blood donors from Kerman. In 
our study , among NAFLD  patients 44% had increased  enzyme activity. This indicates 
the NAFLD patients have chronic inflammation of the liver.” 
 
 
 
 
PLATELET COUNT AND  MPV CORELATION WITH NAFLD: 
 
“Mean platelet volume is increased in 70% patients in NAFLD. This indicates platelet 
volume and atherosclerosis is common among NAFLD patients.” 
 
“Among obese patients MPV was increased. The mean MPV for BMI >30 was 11.6 
which was significant .This indicates that obese individuals have platelet dysfunction and 
they are more prone to early atherosclerosis and cardiac morbidity. In the study , “Mean 
platelet volume in patients with non-alcoholic fatty liver disease” by  Ozhan H, Aydin 
M et al states that  NAFLD patients had significantly higher body mass index compared 
to the control cases. Among biochemical variables, fasting plasma glucose and 
triglyceride were significantly higher in the NAFLD group. NAFLD cases also had lower 
platelet count and higher MPV . MPV was positively correlated with AST , ALT level 
and the presence of NAFLD but negatively correlated with platelet number and 
creatinine. In another study “Mean platelet volume in biopsy-proven non-alcoholic fatty 
liver disease” by Celikbilek M et al  showed that MPV, an indicator of platelet activation, 
increased in biopsy proven NAFLD patients.” 
 
MEAN PLATELET VOLUME AS A MARKER FOR CV RISK IN NAFLD: 
“In our study , 53% NAFLD patients had electrocardiographic changes. This indicates 
NAFLD  is associated with cardiovascular disease. Also these ECG changes were 
associated with NAFLD patients with high MPV( 11.6 fL).  In this study conducted by 
Naim Alkhouri, Gaurav Kistangari et al, “ Mean Platelet Volume as a Marker of 
Increased Cardiovascular Risk in Patients with Nonalcoholic Steatohepatitis” ,there 
was a stepwise significant increase in MPV levels from patients with normal biopsies to 
patients with simple steatosis to patients with NASH (9.5 fL, 10.2 fL, and 11.3 fL, 
respectively). Moreover, there was a significant correlation between MPV levels and the 
individual histological features of NASH on liver biopsy including inflammation, 
steatosis , ballooning  and fibrosis .” 
 
 
 
 
 
 
 
 
 
 
CONCLUSION: 
“1.Among 100 patients , NAFLD are more common in age group of  40 to 50 years ( 
56%). NAFLD is more common among males (72%) when compared to female (28%).” 
“2. NAFLD is common among obese individuals with BMI 26 to 30 (61%). Among 
NAFLD patients  68 % of the patients had TGL >150 mg/dl and 66 % of patients have 
HDL cholesterol < 40 mg.dl. Among NAFLD 50% had waist circumference in the range 
of around 76 to 90 cm.” 
“3. In our study also diabetes mellitus was common in NAFLD individuals. Among 
NAFLD  patients 65% had fasting blood sugar >100mg/dl. This indicates diabetes 
mellitus plays role in the pathology of NAFLD.” 
“4. In our study , among NAFLD  patients 44% had increased  enzyme activity. This 
indicates the NAFLD patients have chronic inflammation of the liver.  Also in our study 
in  NAFLD patients whose ALT was high , MPV was also tend to be high. This shows 
the positive correlation between ALT and MPV. The mean MPV was 10.2 in elevated 
ALT patients.” 
“5. Mean platelet volume is increased in 70% patients in NAFLD. This indicates platelet 
volume and atherosclerosis is common among NAFLD patients. 
Obese patients had increased MPV . The mean MPV for BMI >30 was 11.6 which was 
significant .This indicates that obese individuals have platelet dysfunction and they are 
more prone to early atherosclerosis and cardiac morbidity.” 
“6. In our study , 53% NAFLD patients had electrocardiographic changes. This indicates 
NAFLD is associated with cardiovascular disease. Also these ECG changes were 
associated with NAFLD patients with high MPV( 11.6 fL). This association shows that 
MPV can be used to asses cardiovascular risk in NAFLD patients.” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY: 
“The study “ MEAN PLATELET VOLUME AS A NOVEL MARKER FOR 
INCREASED CARDIOVASCULAR RISK IN PATIENTS WITH NON ALCOHOLIC 
FATTY LIVER DISEASE” was done to assess whether MPV is increased in NAFLD 
patients and to investigate whether this increased MPV is associated with increased 
cardiovascular disease in patients with NAFLD .” 
 
“100 patients were selected carefully and were evaluated on clinical , social and 
laboratory aspects after institutional ethical clearance .  NAFLD patients were selected on 
the basis of Ultrasonographic findings and blood tests were carried out to determine 
MPV. ECG was taken to all patients and was sorted into two groups as patients with ECG 
changes and patients without . Those patients with ECG changes had mean MPV value 
increased and thus MPV can be used as novel marker to assess cardiovascular risk. Also 
MPV showed a positive correlation with ALT which also indicates that MPV is an  
inflammatory  marker. This study also demonstrates significant correlation between MPV 
and metabolic syndrome.” 
“Although MPV is a cheap and simple test, it is usually neglected by clinicians. Its 
importance in patients with NAFLD is not only in the prediction of the disease but also in 
the prediction of cardiovascular mortality in patients with already diagnosed NAFLD. 
Our data explain in part the increased cardiovascular mortality in patients with NAFLD” 
 
 LIMITATIONS OF THE STUDY: 
 
“1.The small sample size and the cross-sectional design impose the data obtained to be 
confirmed in wider trials.” 
“2.The diagnosis of NAFLD was performed by using the non-invasive Ultrasonographic 
guidance  instead of liver biopsy that represents the gold standard.”  
“3.For assessing cardiovascular risk  among NAFLD patients , only ECG was taken.” 
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LIST OF ABBREVIATIONS: 
NAFLD : Non alcoholic fatty liver disease .  
MPV : Mean platelet volume. 
METS: Metabolic syndrome. 
NASH: Non alcoholic steatohepatitis. 
NAFL: Non alcoholic fatty liver. 
UPR: Unfolded  protein  response. 
PERK : Protein kinase RNA like ER kinase. 
IRE 1 α: Inositol requiring protein. 
ATF 6 : Activating transcription factor. 
SREBP: Sterol responsive element binding protein. 
ROS : Reactive oxygen species. 
SFA: Saturated fatty acid 
KC: Kupfer cells. 
HSC: Hepatic stellate cells 
SOCS: Supressor of cytokine signalling. 
CCL2: C Chemokine ligand 2. 
AMPK: AMP activated protein kinase. 
 
 
 
 
                                                       PROFORMA 
Name: 
Age / Sex: 
IP / OP no: 
Occupation: 
 
Presenting complaints: 
H/o right upper  abdominal pain 
H/o heaviness over right upper abdomen 
H/o easy fatigue 
H/o nausea & anorexia 
H/o generalised weakness 
H/o itching 
 
Past History: 
H/o DM/SHT/CKD/CLD/VIRAL HEPATITIS/THYROID DISEASE 
H/O Blood transfusion/HIV/tattoing/hepatotoxic drugs/oc pills 
 
Personal history 
alcoholic/ non alcoholic 
smoker/ nonsmoker 
 Clinical Examination: 
GENERAL EXAMINATION 
                                 Conscious  
                                 Pallor 
                                 Icterus 
                                 Clubbing 
                                 Goitre 
                                 Lymphadenopathy/signs of liver cell failure. 
                                 Scratch marks/tattoo marks 
VITALS 
                                Pulse rate 
                                Blood pressure 
                                Height 
                               Weight 
                                BMI 
                               Waist : hip ratio 
 
SYSTEM  EXAMINATION 
 Oral cavity 
 
Abdomen  
 
CVS 
 RS 
 
CNS 
 
 
Laboratory investigations: 
 
1.Hemoglobin,complete blood count, Mean platelet volume 
2.Blood urea, serum creatinine, blood glucose(FBS,PPBS) 
3.Liver function tests including serum bilirubin,transaminases. 
4.Viral markers 
5.Fasting lipid profile. 
6.USG ABDOMEN 
7.ECG 
 
Diagnosis 
 
 
 
 MASTER CHART 
S.N AGE SEX BMI W.C FBS SBP DBP AL
T 
AST T.C LDL HD
L 
TGL PLT.
C. 
MPV E
C
G 
1 43 M 25.5 90 110 140 90 54 51 225 120 45 156 1.5 10.1 P 
2 45 M 22.3 87 100 130 85 15 14 145 89 46 145 1.5 9.8 A 
3 42 M 21.4 78 98 120 80 55 48 222 135 48 112 3.1 8.7 A 
4 50 M 26 91 118 135 70 10 18 155 118 39 152 2.3 9.5 A 
5 49 M 25.7 90 123 140 95 50 55 232 138 40 212 3.2 10.2 P 
6 62 M 25.3 89 121 120 90 20 15 158 122 41 209 1.4 10.2 P 
7 29 M 22.4 76 87 165 95 25 20 177 78 39 167 2.2 9.2 A 
8 24 F 25.6 82 130 140 85 15 19 198 98 45 121 3.3 10.2 P 
9 30 M 29.4 98 145 130 100 55 45 255 120 38 244 2.9 11.2 P 
10 43 F 26.3 90 134 120 90 10 18 166 156 43 134 2.3 11.1 P 
11 41 M 21.6 78 100 110 80 25 22 176 87 44 154 2.8 9.3 A 
12 52 M 27.3 96 187 155 75 22 30 178 156 47 231 2.5 10.2 P 
13 56 M 26.5 93 167 120 70 20 28 155 123 56 157 1 9 A 
14 50 F 24.9 87 101 110 75 15 24 146 87 53 214 2.2 11.2 P 
15 42 M 21.9 76 95 170 95 10 19 155 97 58 112 1.2 8 A 
16 62 M 26 89 109 130 80 44 45 232 110 43 145 3.5 8.2 A 
17 32 F 22 62 92 140 85 15 19 177 76 46 113 2.8 7.9 A 
18 47 M 21.7 75 93 110 80 28 20 156 88 32 121 1.4 7.6 A 
19 42 M 24.9 78 80 165 75 39 40 227 115 48 154 3.4 7.9 A 
20 38 F 32 104 212 120 100 46 38 265 127 33 265 2.5 11.1 P 
21 44 M 23.6 88 100 160 80 29 20 147 98 46 154 1 8.5 A 
22 47 M 30 102 231 130 85 18 10 150 195 34 254 1.4 11.9 P 
23 43 M 28.5 99 211 110 75 17 24 167 178 36 232 2.8 10.2 P 
24 44 F 24.3 70 83 150 105 50 46 245 130 48 154 1.6 7.5 A 
25 39 M 29.3 100 209 170 75 23 29 177 197 38 199 1.5 10.9 P 
26 42 M 25.3 87 111 140 80 30 20 177 115 43 143 2.2 8.9 A 
27 50 F 22.5 76 92 110 85 17 20 155 116 46 154 1 7.2 A 
28 58 M 27.8 97 165 145 90 55 50 243 119 32 234 1.4 11.1 P 
29 39 M 29.9 101 187 110 95 18 20 150 199 34 265 3.1 11.6 P 
30 41 M 25.1 88 125 120 85 18 20 148 88 47 223 1.1 8.5 A 
31 66 M 22 78 92 120 110 20 15 155 99 46 132 1 8.3 A 
32 54 F 22.6 63 93 110 70 43 45 222 110 47 102 3.4 8.6 A 
33 44 F 22.4 78 100 120 75 25 30 155 86 45 108 1.6 8.3 A 
34 39 M 29 99 190 130 70 20 25 160 117 34 232 1.8 11.8 P 
35 50 M 30 102 211 110 100 37 35 234 115 37 276 2.4 11.5 P 
36 43 F 21.5 70 89 120 70 45 40 254 118 46 114 1.6 7.8 A 
37 45 M 27.2 98 178 110 75 44 54 222 110 36 212 1.5 11.1 P 
38 61 M 20 73 98 140 70 40 52 227 112 62 123 2.1 7.9 A 
39 49 F 28.2 84 190 110 95 18 25 160 187 37 198 1.2 11 P 
40 42 M 25.4 75 118 110 80 25 19 165 116 45 156 1.2 8.9 A 
41 60 F 25.3 81 112 120 75 65 68 255 110 54 158 2.7 10.2 P 
42 38 F 26.6 80 167 120 70 55 45 245 126 36 159 1.8 9.4 P 
43 46 M 25.6 76 145 110 75 30 33 180 112 36 132 1.9 9.2 A 
44 48 M 25.3 80 187 135 90 67 65 233 109 43 134 2.7 9.4 A 
45 37 F 19.9 57 98 110 85 40 45 210 80 45 113 3.1 8.3 A 
46 57 M 28.4 90 187 120 90 15 20 165 145 38 187 2.4 11.3 P 
47 45 M 26.4 88 197 110 70 78 75 265 134 32 156 2.2 11.2 P 
48 55 M 26.7 83 194 120 90 16 20 165 167 36 154 1.3 9.7 P 
49 51 F 25.7 80 192 155 95 20 29 156 124 41 198 3.2 10.2 P 
50 49 F 21 71 91 130 90 25 23 145 89 40 114 3.3 7 A 
51 50 M 26.5 87 185 155 100 72 65 255 113 52 165 3 10.2 P 
52 53 M 28.9 91 298 165 110 12 16 176 145 37 190 2.1 11.8 P 
53 65 M 24 76 93 135 90 18 29 167 65 45 123 1.5 9.5 A 
54 53 M 23 72 90 135 100 45 48 222 112 43 111 2.8 8.4 A 
55 55 M 22.6 72 99 155 85 70 73 227 98 42 106 2.5 9.4 A 
56 42 M 26.8 82 155 110 70 25 29 154 134 37 145 3.2 10.2 P 
57 60 F 21 74 93 165 75 35 30 177 89 34 102 1.2 8.6 A 
58 50 M 25.9 88 165 120 95 30 23 156 132 37 112 1.8 8.5 A 
59 51 M 25.6 90 164 110 85 16 12 165 154 39 155 1.3 9.3 A 
60 55 M 26.1 91 132 135 70 82 74 276 132 36 165 2.5 10.2 P 
61 41 F 24 73 92 140 75 18 10 155 113 45 132 2 9.3 A 
62 65 M 27.3 99 167 135 80 16 35 165 167 37 231 2.1 10.9 P 
63 53 F 29.6 87 234 110 80 13 20 155 156 40 242 3.1 11.1 P 
64 49 M 22.4 78 95 145 75 22 37 154 97 43 132 2.5 10.1 P 
65 39 F 25.6 88 176 130 90 84 66 245 87 40 165 2.7 8.9 A 
66 37 F 28.5 90 198 120 100 55 54 190 90 33 212 3.7 10.2 P 
67 43 M 26.2 91 134 110 75 18 22 162 113 56 165 2.6 10.2 P 
68 41 M 30 101 276 120 95 22 10 153 176 33 287 1.7 11.5 P 
69 63 M 26.5 99 143 150 85 50 55 210 113 65 232 2.1 11 P 
70 46 M 20.5 75 91 110 80 18 22 176 112 34 113 2.7 10.2 P 
71 39 F 31.9 102 298 120 105 14 19 154 156 33 267 1.5 12 P 
72 55 M 21.4 72 90 130 100 76 70 265 98 46 112 3 9.5 A 
73 49 M 30 103 243 155 90 28 20 154 176 35 254 2.5 11.5 P 
74 56 F 22.5 76 88 110 85 15 38 155 98 46 103 2.9 9.2 A 
75 52 M 30.3 101 232 110 105 22 10 165 154 35 254 1 11.7 P 
76 64 M 21.6 70 70 125 70 25 18 176 110 57 102 2.9 9.3 A 
77 66 M 27.4 99 154 150 80 66 58 245 189 43 265 1.7 12 P 
78 53 M 26.8 95 123 120 75 18 25 167 94 35 154 1.9 11.2 P 
79 55 M 29.9 102 169 130 70 45 39 200 143 31 287 4.2 12 P 
80 51 M 20.7 80 74 110 110 13 10 154 87 45 90 1.8 9.2 A 
81 56 M 26.8 90 156 155 75 43 39 221 116 42 156 1.9 9.6 A 
82 64 M 28.5 92 165 120 70 65 55 234 167 34 212 3.1 10.9 P 
83 57 F 20.9 76 77 130 80 10 15 155 89 57 95 2.9 9.2 A 
84 52 M 26.4 92 143 110 85 45 49 230 184 43 210 3.3 11 P 
85 49 M 25.7 91 176 160 100 12 10 154 87 56 102 1.4 10.3 P 
86 65 M 25.3 90 156 140 75 20 10 165 113 56 211 1.3 8.9 A 
87 53 M 27.8 94 198 135 80 62 55 255 145 54 190 3 11 P 
88 67 F 30 104 267 160 90 45 38 222 178 35 199 2.4 11.3 P 
89 54 M 22.8 78 76 135 85 25 20 160 98 32 115 2.8 10.2 P 
90 56 M 26.7 80 156 110 80 10 15 167 114 41 121 3.3 10.3 P 
91 50 M 20.5 70 87 135 95 12 10 153 89 43 99 1.7 9.3 A 
92 56 M 26.8 90 145 170 85 55 30 255 115 35 143 1.6 10.5 P 
93 45 M 25.6 89 143 130 80 20 22 154 134 56 114 3.1 8.4 A 
94 53 M 20.6 79 89 120 90 15 10 161 92 42 115 2.7 8.3 A 
95 56 F 23.7 65 92 165 95 10 15 172 93 32 105 1.4 8 A 
96 51 M 21.6 76 76 110 100 25 20 156 97 45 90 1.1 8.2 A 
97 43 M 26.8 98 176 120 95 44 40 211 115 45 113 1.4 9.9 P 
98 55 M 25.3 91 156 160 85 20 15 154 119 33 87 3.2 8.4 A 
99 41 F 27.8 82 212 140 90 56 43 245 189 37 156 2.9 10.3 P 
100 42 F 28.9 82 190 165 90 20 19 177 127 37 189 2 11.1 P 
BMI : Body mass index 
W.C : Waist circumference. 
FBS: Fasting blood sugar. 
SBP: Systolic blood pressure. 
DBP: Diastolic blood pressure. 
T.C: Total cholesterol. 
LDL: Low density lipoprotein 
HDL: High density lipoprotein. 
TGL: Triglycerides 
PLT.C : Platelet count 
MPV : Mean platelet volume 
  
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
